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Economic evaluation of open vs endovascular
repair of blunt traumatic thoracic aortic injuries
Michael Zhen-Yu Tong, MBA, MD, Pavan Koka, MD, and Thomas L. Forbes, MD, London, Ontario,
Canada
Objectives: During the last decade, endovascular repair (EV) has replaced open surgical repair (OSR) as the preferred
method of treatment of blunt traumatic thoracic aortic injuries (BTAIs) at many trauma centers. This has resulted in
reductions in mortality, length of stay, and major complications, including paraplegia, with the added expense of the
initial endograft, subsequent surveillance, and reinterventions. The purpose of this study was to conduct an economic
evaluation comparing these two methods of repair.
Methods: We performed an economic comparison of EV and OSR for the treatment of BTAI using a decision tree analysis
with transition points derived from our institution’s experience and through a review of the literature. Over a 15-year
period (1991-2006), 28 patients with BTAI were treated at our center (15 EV, 13 OSR). Costs were obtained from our
hospital’s case costing center, the Ontario Case Costing Initiative, Ontario’s Drug Benefit Formulary, and Ontario’s
Schedule of Benefits for physician costs. Our center’s results were then combined with those from the literature to arrive
at an economic model.
Results: These combined results revealed that EV, when compared to OSR, resulted in decreased early mortality (7.2% vs
22.5%), decreased composite outcome of mortality and paraplegia (7.7% vs 27.6%) and decreased composite outcome of
mortality and major complication (42.5% vs 69.8%). Patients undergoing EV also had shorter intensive care unit stays
(12.2 vs 15.3 days), total hospital length of stays (22.5 vs 28.6 days), and ventilator days (8.0 vs 9.2 days). Additionally,
patients undergoing EV had decreased total 1-year costs compared with OSR ($70,442 vs $72,833).
Conclusions: EV repair of BTAIs offers a survival advantage as well as a reduction in major morbidity, including
paraplegia, compared with OSR, and results in a reduction in costs at 1 year. As a result, from the cost-effectiveness point
of view, EV is the DOMINANT therapy over OSR for these injuries. ( J Vasc Surg 2010;52:31-8.)Blunt traumatic thoracic aortic injuries (BTAIs) are
responsible for up to 16% of motor vehicle collision
(MVC)-related deaths, and 85% of patients who sustain a
thoracic aortic laceration will exsanguinate at the scene.1-4
Patients following a MVC can suffer frommultiple injuries,
and the prompt recognition and diagnosis of a BTAI is
critical. Prior to the last decade, the surgical standard for
these patients has been emergent open surgical repair
(OSR) of the aorta via a thoracotomy.5-7
Despite advances in open repair, patients undergoing
OSR of a BTAI still carry significant mortality as high as
54% and morbidities that include bleeding, stroke, cardiac
events, respiratory failure, renal failure, sepsis, bowel isch-
emia, and paraplegia that can occur in 7% of OSR cases
according to a recent meta-analysis.8-15
Since 1991, endovascular stent grafts have been used in
the repair of abdominal aortic aneurysms (AAAs) and have
become the standard of care at many centers.7,16,17 Short-
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doi:10.1016/j.jvs.2010.01.087term results of endovascular aortic repair have demon-
strated reduced morbidity, mortality, and decreased hospi-
tal and intensive care unit (ICU) length of stay (LOS)
compared with open technique. Advances in the field have
allowed for extension of this technology in treating
BTAI with decreased morbidity and mortality compared
with OSR.9,15,18,19 A recent meta-analysis showed a signif-
icant reduction in perioperative mortality (2% vs 14%),
30-day mortality (8% vs 20%), and paraplegia rates (0% vs
7%) compared with OSR.15 On the other hand, endovas-
cular repair (EV) has a higher reintervention rate and has an
initial device-associated cost.15,20 Although EV of AAAs
has inconsistently shown to be cost effective, the mortality,
morbidity (paraplegia rate) and LOS benefits are signifi-
cantly greater for patients with BTAI than for elective
aneurysm repair.15, 21-24 Therefore, we postulate that the
cost savings from EV repair of BTAIs would outweigh the
cost of the device, surveillance, and reinterventions. Cur-
rently, there are no studies that have evaluated the cost
effectiveness of EV in the setting of thoracic aortic injury.
The purpose of the present study is to compare costs
associated with these twomethods of repair of BTAIs (Fig).
METHODS
The analysis was taken from the primary viewpoint of
the Ontario provincial government, a single payer of health
care, for the total cost of care for the first year. Loss of
productivity or costs beyond 1 year of follow-up was not
considered in this study. This study received approval from
31
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Research Involving Human Subjects.
Data collection. All patients between 1991 and 2006
at a single tertiary care university hospital trauma center who
suffered a BTAI were included in this study. Patients’ infor-
Fig. Pathway for thoracic aortic injury incomation was collected retrospectively from the hospital chart.Patients were included if they met all of the following: age
18 years, blunt trauma, injury severity score (ISS) 12,
thoracic aortic injury secondary to blunt trauma, and at-
tempted or successful repair of thoracic aortic injury via
either EV or OSR. Patients were excluded if they died prior
ating major resource utilization outcomes.to repair, or if they did not undergo repair.
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were mortality, paraplegia, composite outcome of mortal-
ity, and major morbidity (paraplegia, pneumonia/respira-
tory complications/respiratory failure, renal failure requir-
ing dialysis, and endoleak), ventilator time, mean ICU
LOS, and total hospital LOS. In addition, patients’ medical
records, surgeons’ office charts, and radiology reports were
also reviewed for items that would contribute to resource
utilization paid for by the government such as number of
physician visits, computed tomography (CT) scans, reinter-
ventions, and utilization of health services by paraplegic
patients if available.
Literature data search. Our search criteria included
English language studies involving adults (age  18),
thoracic aortic injury, managed with either OSR or en-
dovascular stent graft. The following electronic data-
bases, Medline, EMBASE, Cochrane, DARE, and
Health technology assessment database were searched
from the date of their inception to 2009.4,7,12,25-41 Data
collected included mortality, paraplegia/paraparesis
rate, renal failure, respiratory complications, conversion
to open repair, endoleak rate, ICU LOS, hospital LOS,
and ventilator time. To incorporate results from all rele-
vant studies, all outcomes, including our own center’s
outcomes, were pooled and the weighted average of each
outcome was used for this analysis.
Resource utilization. The costs for the initial hospi-
talization and surgical procedure following injury were
obtained from our hospital’s Case Costing Center
(CCC),42 and depending on which costs were available, the
following methods were used to arrive at a final cost for
each patient in order of priority:
(1) Ontario Case Costing Initiative (OCCI)-estimated
cost was derived by finding the cost for the specific
diagnosis and the specific procedure based on diagnosis-
related group or case mix groups.43
(2) Patient-specific costs for patients from our hospital:
actual costs for the entire hospital stay were available
through the hospital CCC for patients admitted to
hospital and are broken down into direct variable cost
(operating room, endograft cost, ICU, diagnostic im-
aging, pharmacy, labs, etc), direct fixed cost (nursing,
administrative, finance, human resources, plant opera-
tions, etc), and indirect cost (lighting, electricity, wa-
ter, etc).42 For patients undergoing OSR, six patients
repaired prior to 1996 were not included in the base
analysis due to restructuring changes to the health care
system after that period, which resulted in significant
reduction in hospital LOS and overall resource utiliza-
tion. Therefore, cost data were available for 22 of the
28 originally treated patients.
(3) Estimated hospital costs for patients with missing cost
information: all relevant items were first identified and
the corresponding ICD-10 codes were obtained from
hospital records. Hospital costs for all patients treated
in 2005 were obtained from CCC. Using these item-
ized costs, an overall estimate was made for patientsbased on the treatment they received, as well as addi-
tional procedures, complications, and ICU and total
hospital LOS.44
(4) All costs for physician services were taken from On-
tario’s Schedule of Benefits and incorporated into costs
for each outcome.45
The costs were adjusted for 2005 $CANusingmethods
previously described.46 For cost of services provided to
paraplegics, we could not obtain data from our rehabilita-
tion hospitals. Therefore, we relied on costs data previously
published describing the utilization of health services fol-
lowing spinal cord injury.47,48
Clinical outcomes. For the cost-effectiveness analysis,
an observational pathway was constructed (Fig). Recogniz-
ing that we could not study all outcomes, we focused on
those that were the most serious and those that resulted in
the greatest resource utilization: death, respiratory compli-
cation (pneumonia, prolonged ventilation, respiratory fail-
ure), renal failure requiring renal replacement therapy,
paraplegia, ICU LOS, total hospital LOS, and ventilation
time. We believed that the remaining outcomes would be
similar in both treatment groups. Additional outcomes
specific to EV were endoleak and conversion to OSR.
For the transition points within themodel, we obtained
a range from the published literature and from our institu-
tion’s experience and used the weighted mean for our
analysis. Mortality rates from patients with paraplegia, renal
failure and respiratory failure were obtained from the ICU
and trauma literature.49-51 Expert opinion was sought for
all other transition points where no published data was
available. The probability for each outcome is then multi-
plied by the cost associated for each outcome to give the
expected cost for both OSR and EV. Cost associated with
ICU LOS, total hospital LOS, and ventilator time was then
added to each outcome to arrive at the final cost. Analysis
was done based on intention to treat, ie, cost associated
with conversion to OSR counted toward the cost of the EV
cohort.
Cost-effectiveness analysis. We used OSR as the ref-
erence procedure, therefore, EVwas deemedDOMINANT if
it reduced cost and improved outcomes (reduced mortality
and morbidity). If EV had a higher cost but improved
outcomes, an incremental cost-effective ratio would be
calculated. If EV had inferior outcomes and increased cost,
it was deemed DOMINATED.
RESULTS
The patients’ demographic data were similar in both
groups, and the differences were not statistically different
(Table I). Requirement for concomitant surgical procedure
was not different between the groups nor was the postop-
erative ICU and hospital LOS, although the median ICU
LOS and hospital LOS favored the EV group. The lack of
statistical difference is likely due to the relatively small
numbers in each group. Among the postoperative clinical
outcomes, there were no significant differences in mortal-
ity, renal failure, and pulmonary complication rates. There
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of paraplegia in the OSR group, although this difference
did not reach statistical significance. Follow-up for these
patients was generally poor, but is similar to that in other
series, with only 50% of surviving patients from the open
group and 38% of the surviving EV group returning during
the first postoperative year. Among those in the EV group
who did return for follow-up, a CT scan was performed at
one month and then every six months following to ensure
that no endoleak had developed and that no endograft
migration had taken place. Patients in the OSR group did
not routinely receive postoperative CT imaging. In our
series, there was one endoleak that was recognized imme-
diately following stent deployment and resolved at one
month follow-up in the EV group. No other endoleaks
were present on the CT scans during follow-up.
In our series, there were two patients, both in the OSR
group, who developed paraplegia as a direct complication
of the surgery. These two patients had 19- and 24-day
initial hospital LOS and 104- and 99-day LOS at the
rehabilitation hospital. We were not able to obtain infor-
mation from our rehabilitation hospital regarding the cost
of care of these paraplegic patients. Therefore, a review of
the literature revealed an excellent study with a detailed
outline of the utilization of health services after spinal cord
injury in Alberta and the average cost for the first year.47
The total 1-year cost for each patient represents the sum of
the patient’s total hospital cost, the total follow-up cost,
and additional costs such as rehabilitation for paraplegic
patients or home care nursing visits.
When we added our hospital’s experience to results
from the published literature, there were a total of 431
patients in the OSR group. There was 22.5% mortality rate,
31% respiratory complication rate, 11.3% renal failure rate,
and a 5.1% paraplegia rate. The mean ICU LOS for the
entire cohort was 15.3 days, mean hospital LOS was 28.6
days, and ventilator time was 9.2 days. In the EV group,
Table I. Demographic and injury statistics
Descriptive variable
EV
(n  15)
OSR (recent)
(n  7) P value
Age (y) (mean) 46.2 40.2 .165
Genderb (number male
patients [%]) 10 (67.7%) 5 (71.4%) 1.000
Presenting Glasgow Coma
Scalea Score 10.8 13.7 .077
ISSa 35.2 38.3 .458
AISS, head and necka 3.6 3.0 .537
AISS facea 1.5 1.4 .750
AISS chesta 4.1 4.5 .329
AISS abdomena 2.9 3.5 .210
AISS extremitiesa 2.8 2.8 1.000
Time delay to surgery (h)a 12.1 15.4 .632
AISS,Abbreviated Injury Severity Score; EV, endovascular repair; ISS, Injury
Severity Score; OSR, open surgical repair.
aValues are expressed as means, statistical test is t test.
bValues expressed as number (percentage), statistical test is Fisher exact test.there were a total of 418 patients. This cohort had a 7.18%mortality rate, 26.6% respiratory complication rate, 8.3%
renal failure rate, 0.48% paraplegia rate, 12.2 days mean
ICU LOS, 22.5 days hospital LOS, and 8.0 days ventilator
time. In addition, there was a 2.6% conversion to OSR rate,
7.4% early endoleak, and 0.72% late endoleak rate.
The relevant costs and adjustment rates for estimated
missing costs are presented in Tables II, a, b, and c, online
only. The rationale for the assumptions in ourmodel are listed
in Table II, a. Each patient’s costs was calculated using these
assumptions and compared to actual costs and were deter-
mined to be comparable. The transition points in our pathway
are presented in Table III with the associated cost for each
outcome. To build our decision tree, we made the following
assumptions: 80% of renal failure mortality would also die
from respiratory failure, 35% of endoleak both early and late
would require intervention, and patients with endoleakwould
have a 5% mortality rate (Table IV). With the outcomes and
assumptions presented in Table IV, the probabilities for each
outcome in our decision tree in Table III can be mathemati-
cally calculated. Mortality rates were factored into the ex-
pected cost of each procedure, and each point in Table III
represents a specific outcome, or combination of outcomes.
Our decision tree analysis showed that patients under-
going EV repair had decreased mortality (7.2% vs 22.5%),
decreased composite outcome of mortality and paraplegia
(7.66% vs 27.61%) and decreased composite outcome of
mortality and major complication (42.49% vs 69.84%) and
lower 1-year costs, $70,442 vs $72,833.
DISCUSSION
Advances in endograft technology have led to its utili-
zation in BTAI and have caused a fundamental shift in the
treatment of this high-risk group of patients. As motor
vehicle accidents remain by far the most common cause of
these injuries, these patients will present with potentially
life-threatening injuries, and immediate OSR through a tho-
racotomy may be contraindicated, which can delay definitive
surgery. In a select subset of patients, delayed aortic surgery
does not lead to a significant increase in mortality, however,
delaying can lead to rupture, higher complication rates, and
prolongedhospital stay.52-55EVhas allowed for these patients
to be treated sooner, as these patients can avoid themorbidity
of a thoracotomy, single-lung ventilation, and systemic anti-
coagulation.28, 40 In turn, this has led to a decreasedmortality
rate, decreased morbidity including paraplegia, and decreased
ICU and hospital LOS.4,15,18 EV has now become the stan-
dard of care for BTAI at many institutions.
EV for AAAs has decreased the perioperative morbidity
and mortality, but all-cause mortality and quality of life is
similar to open repair at midterm follow-up.56 The cost
savings obtained from decreased morbidity, mortality, and
decreased LOS at the initial time of surgery is offset by the
cost of the device, continued surveillance, and increased
reintervention rates compared to open repair.21-24 How-
ever, when it comes to traumatic aortic injuries, the differ-
ence in perioperative morbidity and mortality is larger
compared with differences seen for EV for AAAs. There-
fore, the cost savings is also significantly higher, especially
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 1 Tong et al 35Table III. Transitional probabilities based on LHSC and literature outcomes
Terminal outcome
Our cohort
path probabilities
Literature  our hospital
path probabilities Cost
Open surgical repair
Mortality (nonrespiratory, nonparaplegia, nonrenal deaths) 0.154 0.1495 $22,492.31
No acute complications
Uneventful recovery 0.324 0.3770 $30,368.34
Paraplegia
Survive  rehabilitation 0.130 0.0503 $154,696.63
Death 0.000 0.0008 $44,785.96
Respiratory complication
Survive  recovery 0.260 0.2433 $65,603.20
Death 0.065 0.0662 $56,415.89
Renal failure
Survive  recovery 0.065 0.1044 $62,723.48
Death 0.000 0.0086 $54,256.10
ICU LOS 10 15.3 $1,000
Ward LOS 9 13.3 $720
Ventilator days 7 9.2 1 day - $2529.75
2 days - $4397.59
Extra days
3-5 days: $1608.99/day
6-10 days: $1362.71/
day
11-20 days: $1192.04/
day
21-40 days: $982.10/
day
 40 days: $787.93/day
Thoracic endovascular stent graft repair
Converted to OSR
Mortality (nonrespiratory, nonparaplegia, nonrenal deaths) 0.000 0.0039 $$27,092.39
Uneventful recovery 0.000 0.0099 $36,501.79
Paraplegia – survive 0.000 0.0013 $160,830.08
Paraplegia – death 0.000 0.0000 $50,919.41
Respiratory – survive 0.000 0.0064 $71,736.65
Respiratory – death 0.000 0.0017 $62,549.34
Renal – survive 0.000 0.0027 $68,856.93
Renal– death 0.000 0.0002 $60,389.55
EV
Alive – no acute complications
Uneventful recovery 0.599 0.5490 $41,964.85
Late endoleak
Intervention
Survive 0.000 0.0014 $47,374.78
Death 0.000 0.0001 $45,820.71
No intervention
Survive 0.000 0.0027 $42,233.64
Death 0.000 0.0001 $41,964.85
Mortality (nonrespiratory, nonparaplegia, nonrenal deaths) 0.000 0.0044 $30,667.27
Paraplegia
Survive  rehabilitation 0.000 0.0046 $166,293.14
Rehab  late endoleak
Intervention
Survive 0.000 0.0000 $171,703.07
Death 0.000 0.0000 $143,999.00
No intervention
Survive 0.000 0.0000 $166,561.93
Death 0.000 0.0000 $140,143.14
Death 0.000 0.0001 $55,685.91
Respiratory complication
Survive  recovery 0.200 0.2012 $77,199.71
Recovery  late endoleak
Intervention
Survive 0.000 0.0007 $82,609.64
Death 0.000 0.0000 $81,055.57
, ope
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who develops paraplegia, which can cost over $100,000 in
the first year alone.47 Even when considering the cost of the
endograft, cost of conversion to open repair, cost of rein-
tervention and surveillance, we found that patients treated
with EV for traumatic aortic injury cost less than patients
treated with open repair in addition to improved outcomes,
which makes EV for BTAI a DOMINANT therapy.
Our study does have some limitations. The first is the
fact that all the studies in the literature comparing EV to
OSR for BTAI are retrospective in nature with a higher a
percentage of patients treated with OSR in the 1990s and
higher percentage of patients treated with EV more re-
cently. The advances in radiology and trauma during this
time period are possible confounders to the improved
outcomes seen with EV. A randomized controlled trial
would be required to extract the true benefit of EV versus
OSR, however, such a trial is unlikely at this point in time.
Second, patients who undergo repair of BTAI are
young with a mean age of 38.8 years old according to a
recent meta-analysis, and we do not have long-term data
Table III. Continued.
Terminal outcome
No intervention
Survive
Death
Death
Renal failure
Survive  recovery
Recovery  late endoleak
Intervention
Survive
Death
No intervention
Survive
Death
Death
Early endoleak
Intervention
Survive  recovery
Death
No intervention
Survive  recovery
Death
ICU LOS
Ward LOS
Ventilator days
EV, Endovascular repair; ICU, intensive care unit; LOS, length of stay; OSRregarding the durability of the devices and the need for rein-terventionover time.15 In addition, this populationof patients
is difficult to follow, as they have a high tendency to move. In
our cohort of surviving patients, our 12-month follow-upwas
only 43%over the initial 12months.Wehave demonstrated in
our article that for the first year, EV of TAI is less expensive
thanOSR, but whether this difference is sustainable over time
remains to be seen.Whatwill increase the cost of EVwould be
the cost of surveillance and reintervention, but this cost will be
offset, at least partially, by the time value of money and the
decreased paraplegia rate and the costs associated with caring
for patientswith paraplegia,which cost around$5400per year
in perpetuity following the fifth year.47 Additionally, reinter-
vention rates and costs for OSR are not inconsequential.
Third, with any modeling, the information available is
not always complete, and assumptions had to be made
when information was not available. In our decision tree
analysis, the transition points were obtained from the
pooled literature results and from the experience from our
institution. There is significant literature variability in the
type of devices used, the era of the study, the patient popula-
tion, and the management approaches. In addition, patients
r cohort
probabilities
Literature  our hospital
path probabilities Cost
0.000 0.0000 $77,468.50
0.000 0.0000 $77,199.71
0.067 0.0553 $67,315.84
0.000 0.0738 $74,319.99
0.000 0.0200 $79,729.92
0.000 0.0000 $78,175.85
0.000 0.0004 $74,588.78
0.000 0.0000 $74,319.99
0.067 0.0061 $65,156.05
0.000 0.0240 $47,289.78
0.000 0.0013 $44,929.34
0.067 0.0446 $42,148.64
0.000 0.0023 $41,073.48
6 12.2 $1,000/day
7 10.3 $720/day
2 8.0 1 day - $2529.75
2 days - $4397.59
Extra days
3-5 days: $1608.99/day
6-10 days: $1362.71/
day
11-20 days: $1192.04/
day
21-40 days: $982.10/
day
 40 days: $787.93/day
n surgical repair.Ou
pathundergoing OSR and EV were not randomized and the
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However, the consistency in which we observed a decrease in
mortality, paraplegia rate, and the size of this difference sug-
gest that this difference is likely robust and not a type I error.
Although expert knowledge was used to determine some of
the decision node probabilities in our decision tree, the main
driver in the costs difference between the groups are the cost
of paraplegic patients and reintervention rates, which we be-
lieve are robust.
Finally, our study is performed from the perspective of
the Ontario provincial government, a single payer of health
care. The costs structure is unique to our jurisdiction and
although will be comparable to other Canadian provinces,
the conclusions that we reached may not be valid in other
payer systems with different cost structures. The ICU LOS,
hospital LOS, and ventilator time were large drivers of the
cost difference, however, LOS reductions result in less of a
Table IV. Combined literature/our hospital outcome
Combined
outcomes Reference
OSR
Mortality 22.5% (7, 12, 25, 26,
28-41)
Paraplegia 5.1% (12, 25, 26, 28-41)
Renal failure 11.3% (12, 25, 28-31, 33-
36,
38-41)
Respiratory failure 31.0% (12, 25, 28-31, 33-
36,
38-41)
ICU LOS 15.3 days (26, 36-38, 41)
Hospital LOS 28.6 days (34-38, 41)
Ventilator time 9.2 days (31, 41)
EV
Mortality 7.2% (4, 12, 25-30,
32-41)
Paraplegia 0.5% (4, 12, 25-30,
32-41)
Renal failure 8.3% (4, 28, 30, 33-36,
38-41)
Respiratory failure 26.6% (4, 28, 30, 33-36,
38-41)
ICU LOS 12.2 (4, 26, 34-36, 41)
Hospital LOS 22.5 (4, 27, 34-38, 41)
Ventilator time 8.0 (37, 41)
Other outcomes
Respiratory mortality 21.4% (50)
Renal mortality 38.0% (51)
Paraplegia mortality 1.5% (49)
Assumptions
Mortality due to
combined renal
and respiratory
failure
80% of respiratory
mortality
Intervention rate for
endoleak
35%
Mortality rate for
endoleak
5%
EV, Endovascular repair; ICU, intensive care unit; LOS, length of stay;OSR,
open surgical repair.cost reduction in the Canadian healthcare system, comparedwith that of the United States.23 In areas where these cost are
higher, such as theUnited States where ICU costs are approx-
imately $2500 per day, this difference in cost between EV and
OSR will be even higher in favor of the former.57
In conclusion, for patients who present with traumatic
aortic injury, EV decreases morbidity, mortality, and para-
plegia compared with OSR. In addition, the 1-year cost is
less with EV making EV the DOMINANT therapy over
OSR for BTAI.However, long-term durability of the repair
is unknown and long-term follow-up will be required to see
if the cost benefit is maintained over time.
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Relevant cost Cost estimate Adjustment rate for added cost
Base cost for open surgical repair of
thoracic aortic injury with
cardiopulmonary bypass
$26,860.00 (assuming 5 ICU days, 2
ventilator days, 10 ward days)
N/A
ICU day $1020.00 Not adjusted
Ward day $720.00 Not adjusted
Extra ventilator day 1 day - $3372.98
2 days - $5863.45
Extra days
3-5 days add $2145.32/day
6-10 days add $1816.94/day
11-20 days add $1589.39/day
21-40 days add $1309.46/day
 40 days add $1050.57/day
75% actual cost (some overlap with ICU cost)
Cardiopulmonary bypass $6905.00 100% (only if base surgery cost not used)
Repair diaphragm $5221.52 50% - additional surgery
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required
Closed head injury subdural
hematoma subarachnoid
hemorrhage
$23,377.30 50% - additional surgery (burr holes)
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required
Liver laceration splenectomy $7557.00
$8006.84
50% - additional surgery
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required
Upper extremity fracture
Lower extremity fracture
$5202.36
$6191.44
50% - additional surgery
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required
Pelvic fracture $8735.64 50% - additional surgery
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required (undisplaced)
Vertebral fracture $9306.80 50% - additional surgery
37.5% - additional surgery simultaneous with
other surgical procedure
25% - no surgery required (undisplaced)
Pneumonia $30,096.93 (LOS  13 days) 50% - without mechanical ventilation
(primary cause of respiratory problem)
25% - ventilation required (cost will be
significantly accounted for in cost of extra
ventilator days)
12.5% - ventilation required but associated
with respiratory failure (ARDS) – cost will
be significantly accounted for in cost of
treating ARDS
Tracheotomy $2948.54 50% - procedural cost likely on 50%; other
50% accounted for in base cost and ICU/
ward costs
Respiratory failure (ARDS) $61904.40 25% - due to additional cost accounted for by
mechanical ventilation and ICU cost and
base cost
Deep vein thrombosis $4956.08 50% - costs partially accounted for in base
cost and additional ICU/ward costs
Renal failure requiring dialysis
(intermittent or continuous)
$1347.11 per day 75% actual cost (some overlap with ICU cost)
Paraplegia (hospital cost only) 1 day - $1874.54
2nd day - $1653.67
Extra days
3-10 days add $1332.95/day
11-20 days add $983.05/day
20 days add $935.56/day
50% - for ward days
37.5% - for ICU daysCCC, Case Costing Center; ICU, intensive care unit.
tario Drug Bulletin; SR, slow release.
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Resource item U
Initial hospitalization Varies per pat
Vascular surgeon fee $1
Follow-up visit
Hospital clinic visit
Surgeon fee
CT scan $
Emergency room visit
Hospital cost $
Physician fee
Surgeon fee (if seen)
Paraplegic patient costs
Parkwood Hospital cost per day
Rehabilitation $
Long-term care $
Rehabilitation/physical medicine
specialist fees
Initial consultation $
2nd  3rd day assessments $46.15/day
Subsequent visits $29.20/visit
Medical specific reassessment
Discharge assessment
Re-hospitalization
Emergency room hospital cost $
Emergency physician fee
Admitting physician $
Consultation fee admitting
Physician subsequent visit $720.00/day
Hospital bed (ward) $51.19/visit
Home care services (CCAC)
Medication costs
Antispasmodic (Baclofen 20 mg 3/day) $0.5667/20-
ODB $0.6234/20-
After pharmacy mark-up (10%) $8.61/prescr
Pharmacy dispensing fee
Analgesic (Oxycontin 40 mg SR 4/day)
ODB $2.0800/40-
After pharmacy mark-up (10%) $2.2880/40-
Pharmacy dispensing fee** $8.61/ presc
ICU, Intensive care unit; OCCI, Ontario Case Costing Initiative; ODB, Onted to 1 year)
nit cost Data source
ient (Table II, a) CCC/OCCI (minimal contribution)
528.30 Ontario schedule of physician benefits (SoB)
$85.00 CCC
$41.20 Ontario SoB
152.09 CCC
122.95 CCC
$86.10 Ontario SoB
$41.20 Ontario SoB
CCC
594.00
328.00
127.50 Ontario SoB
Ontario SoB
Ontario SoB
$45.90 Ontario SoB
$46.15 Ontario SoB
122.95 Ontario SoB
$86.10 Ontario SoB
127.50 Ontario SoB
$29.20 Ontario SoB
CCC
CCAC
mg tab ODB
mg tab Average rate of 4 pharmacies in London and
used for mark-up and dispensing fee
iption
ODB
mg tab
mg tab Same as above
ription Same as above
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 1 Tong et al 38.e3Table II, c, online only. Average unit costs for base
surgery, complications, and follow-up period from
Ontario Case Costing Initiative project
Relevant cost OCCI43
Base surgical cost (including 5
ICU days, 10 ward days,
2 ventilator days)
Open surgical repair (OSR) $29,989.74
Endovascular stent graft
repair (EV)
$40,889.69a
EV converted to OSR $36,123.19b
Uneventful recovery (routine
follow-up)
OSR () $378.60
EV () $1075.16
Paraplegia
In-hospital cost () $19,728.29 (LHSC-CCC)48
Rehab  follow-up cost () $104,60047
Respiratory complication
In-hospital cost () $35,234.86
Recovery  follow-up cost () cost of follow-up
Renal failure
In-hospital cost () $32,355.14
Recovery  follow-up cost () cost of follow-up
Early endoleak
Diagnosis cost () $183.79 (CT scan  visit)
Intervention () $5141.14
Late endoleak
Diagnosis cost () $268.79 (CT scan  visit)
Intervention () $5141.14
ICU, Intensive care unit; OCCI, Ontario Case Costing Initiative.
aAdditional costs for EV are mainly accounted for by the price ($7525.00) of
the stent graft used (Talent LPS Thoracic Stent Graft [Medtronic AVE,
Santa Rosa, Calif]) and the additional cost ($1475.00) of radiology equip-
ment used in the operating room.
bNo actual cost was available, therefore, assumption that 15% of resources
(x-ray device, percutaneous access devices) for EV were used was made and
so cost is base cost for OSR  15% cost for EV.
